Genesis Drug Discovery & Development (GD3) has bought up New England Discovery Partners (NEDP) as it looks to boost its synthetic and medicinal chemistry offerings.
The CRO acquisition, financial details of which were not released, also helps GD3 enhance its preclinical drug research and discovery services to its pharma and academia clients.
“NEDP's skilled team of chemists, with almost 250 years of combined pharma and CRO experience, will work synergistically with GD3's existing services around uHTS, computational chemistry, and structural biology,” the company said in a statement.
“We’re committed to building an industry-leading, fully integrated drug discovery CRO,” said Eli Mordechai, Ph.D., CEO of Genesis Biotechnology Group. “Adding NEDP is another way to differentiate our capabilities in the early drug discovery space. We're significantly enhancing our portfolio around organic and medical chemistry to better serve our industry partners.”
This comes after the company bought another CRO, NexusPharma, back in the summer.
That deal saw GD3 integrate the company’s collection of patient-derived xenograft models, with a focus on personalized medicine, including models for acquired resistance to targeted therapies.